Taysha Posts $46.6M Q2 Loss, Completes Dosing in Pivotal TSHA-102 Trials, and Extends Cash Runway into 2H 2028
TSHA has more than doubled off its 52-week low of $2.685.
Summary
Taysha Gene Therapies reported a Q2 net loss of $46.6 million, completed dosing in its pivotal TSHA-102 trials for Rett syndrome, and ended the quarter with $455.4 million in cash — enough to fund operations into the second half of 2028 and through a potential BLA approval.
Key Events · Earnings and Guidance · TSHA
-
Q2 Net Loss Widens to $46.6M
Net loss reached $46.6M ($0.13/share) compared with $26.9M ($0.09/share) in Q2 2025, as R&D expenses climbed $18.5M to $38.6M for BLA-enabling manufacturing and clinical trials, while G&A rose $3.5M to $12.1M for commercial readiness.
-
Dosing Complete in Pivotal TSHA-102 Trials
Dosing is now complete in the overenrolled REVEAL pivotal trial (N=17) and the ASPIRE safety trial (N=4) for TSHA-102 in Rett syndrome. As of August 2026, TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across 33 patients.
-
Cash Runway Extended into 2H 2028
Cash and cash equivalents stood at $455.4M as of June 30, 2026, reflecting the $230M follow-on offering completed in June 2026. Management expects this to fund operations into the second half of 2028 and through potential BLA approval of TSHA-102.
-
Topline Data and FDA Feedback Expected 1H 2027
The 6-month interim analysis of the REVEAL pivotal trial, which may serve as the basis for a BLA submission, is expected in 1H 2027, along with FDA feedback on the BLA pathway. Completion of the BLA-enabling PPQ manufacturing campaign is expected in Q4 2026.
Analysis · TSHA · Life Sciences
A near-doubling of R&D spend to advance TSHA-102 toward a BLA drove Taysha's wider Q2 net loss. Dosing is now complete in both the pivotal REVEAL trial and the ASPIRE safety study, de-risking the clinical timeline ahead of topline data and FDA feedback expected in 1H 2027. The $455.4M cash position, strengthened by the recent $230M follow-on, funds operations through potential approval and removes near-term financing overhang. An expanded partnership with Catalent adds commercial manufacturing readiness. For this pre-commercial biotech, the 1H 2027 clinical readout stands as the binary event that will define its future.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TSHA was trading at $6.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $2.69 to $7.30. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.